Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus MedicalBSP:G2ME34 26 Altman Z-Score is 2.92 as of Aug. 11, 2026, which is 86% below its 10-year median of 21.47. GuruFocus rates BSP:G2ME34 with a GF Score™ of 26/100 and a GF Value™ of R$58.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 808 Medical Devices & Instruments companies, Globus Medical ranks better than 85.02% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 11.38 is strong.
Globus Medical has a Altman Z-Score of 2.92, indicating it is in Grey Zones. This implies that Globus Medical is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Globus Medical's Altman Z-Score or its related term are showing as below:
BSP:G2ME34'
s Altman Z-Score Range Over the Past 10 Years
Min: 4.62 Med: 21.47 Max: 36.99
Current: 11.38
During the past 13 years, Globus Medical's highest Altman Z-Score was 36.99. The lowest was 4.62. And the median was 21.47.
Globus Medical (BSP:G2ME34) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Globus Medical Altman Z-Score Related Terms
Globus Medical Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Globus Medical's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:G2ME34 vs PODD, BRKR, GKOS: Altman Z-Score Comparison
For the Medical Devices subindustry, Globus Medical's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Globus Medical's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Globus Medical's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.3163
+
1.4
*
0.2782
+
3.3
*
0.1241
+
0.6
*
1.9141
+
1.0
*
0.5922
=
2.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Globus Medical (BSP:G2ME34) has a Altman Z-Score of 2.92 as of Aug. 11, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Globus Medical and its competitors. This is 86% below median its historical median of 21.47. Over the past decade, Globus Medical's Altman Z-Score has ranged from 4.62 to 36.99. According to the industry distribution chart, Globus Medical ranks #121 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 15%.
Is Globus Medical's Altman Z-Score too high?
Globus Medical's current Altman Z-Score of 2.92 is 86% below median its 10-year median of 21.47. Over the past 10 years, this metric has ranged from a low of 4.62 to a high of 36.99. The Medical Devices & Instruments industry median Altman Z-Score is 3.10. Globus Medical's value of 2.92 is 5.7% below this industry median. Based on the distribution chart, Globus Medical ranks #121 out of 808 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Globus Medical has a GF Score™ of 26/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's Altman Z-Score compare to PODD and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #121 out of 808 companies for Altman Z-Score. This places Globus Medical in the top 15% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.10. Globus Medical's value of 2.92 is 5.7% below this benchmark. Historically, Globus Medical's own Altman Z-Score has ranged from 4.62 to 36.99 over the past decade. While the company's 10-year median is 21.47 vs. the industry median of 3.10, Globus Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.10, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current Altman Z-Score of 2.92 is 5.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Globus Medical and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current Altman Z-Score is 2.92, which is 86% below median its own 10-year median of 21.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (BSP:G2ME34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$58.52, compared to a current price of R$52.00 — trading 11.1% below its estimated fair value. The current Altman Z-Score is 2.92, which is 86% below median its 10-year median of 21.47 and 5.7% below the Medical Devices & Instruments industry median of 3.10. Globus Medical's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Globus Medical (BSP:G2ME34), the current Altman Z-Score is 2.92 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (BSP:G2ME34) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of R$52.00 is trading 11.1% below its estimated GF Value™ of R$58.52.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for BSP:G2ME34:
Altman Z-Score: 2.92 (86% below median its 10-year median of 21.47)
GF Value™: R$58.52 vs. price of R$52.00 (11.1% below fair value)
Industry Position: 5.7% below the Medical Devices & Instruments median (#121 of 808)
No single metric tells the full story. See the BSP:G2ME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
26GF Score
Get the complete analysis for BSP:G2ME34
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:G2ME34 has been successfully added to your 
